Vera Therapeutics
Open
$35.45
Prev. Close
$35.46
High
$35.46
Low
$35.45
Market Snapshot
$2.29B
-7.6
-2.75
249
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 249 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. The company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. The company retains all global developmental and commercial rights to atacicept and MAU868.
emptyResult
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 249 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. The company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. The company retains all global developmental and commercial rights to atacicept and MAU868.
Recently from Cashu
Vera Therapeutics Highlights Mielle's Kalahari Melon & Aloe Vera Collection for Textured Hair
Mielle's Innovative Approach to Textured Haircare Mielle, a renowned textured haircare brand from Merrillville, Indiana, introduces its Kalahari Melon & Aloe Vera collection, designed specifically for…
Vera Therapeutics Announces Mielle's New Kalahari Melon & Aloe Vera Haircare Collection Launch
Mielle Launches Innovative Haircare Collection for Textured Hair Mielle, a prominent textured haircare brand based in Merrillville, Indiana, unveils its new Kalahari Melon & Aloe Vera collection, spec…
WHP Global Acquires VERA WANG, Expanding Luxury Fashion Brand Portfolio and E-Commerce Reach
WHP Global Enhances Brand Portfolio with VERA WANG Acquisition WHP Global, a leading brand management firm headquartered in New York, makes significant strides in the fashion industry with its recent…
WHP Global Acquires VERA WANG Brand to Enhance Fashion Portfolio and Digital Presence
WHP Global Acquires VERA WANG Brand, Strengthening Portfolio in Fashion Sector In a significant move within the fashion industry, WHP Global announces its acquisition of the intellectual property righ…